Cephaloglycin. Clinical and laboratory experience with an orally administered cephalosporin

Cephaloglycin was evaluated in vitro and in the treatment of urinary tract infection. Over 90% of strains of Escherichia coli, Proteus mirabilis, and Klebsiella-Aerobacter were inhibited by concentrations of cephaloglycin achieved in the urine of patients receiving cephaloglycin as therapy for urinary tract infections. Peak serum concentrations of cephaloglycin inhibited all strains of group A streptococci and Diplococcus pneumoniae and some strains of Staphylococcus aureus, E coli, and p mirabilis. Twenty-three patients with urinary tract infection were treated with cephaloglycin. Most of the patients had structural abnormalities or chronic infection of the urinary tract. All patients were free of bacteriuria during therapy and 11 patients (48%) were abacteriuric one month after discontinuation of therapy. Diarrhea and eosinophilia were the only side effects noted and did not constitute a major problem.